American Gene Technologies®
In The News
AGT Spins Out Addimmune, Focusing on Functional HIV Cure
Original Post on Genengnews By: Alex Philippidis According to CEO Jeff Galvin, the cell and gene therapy developer hopes its Addimmune spinout will pick up where AGT leaves off in developing a one-time treatment for HIV, in light of positive early data. A leading…
Read More
American Gene Technologies Spinoff Sets Sights on Advancing Cell Therapy for HIV
Original Post on Precision Medicine Online By: Jessica Kim Cohen NEW YORK – American Gene Technologies (AGT), a 15-year-old privately held biotech firm, is spinning off its HIV drug development program into a separate company that will exclusively focus on advancing therapeutics against the AIDS-causing virus. The…
Read More
CityBiz: Interview with Jeff Galvin, CEO & Founder of American Gene Technologies and Addimmune
Original Post on Citybiz By Edwin Warfield Jeff Galvin is the CEO and Founder of American Gene Technologies®. He earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety…
Read More
Raif Derrazi Interviews Jeff Galvin on HIV Clinical Trial Updates & Addimmune
CEO Jeff Galvin joins HIV activist and Youtube creator Raif Derrazi to discuss the launch of Addimmune™ – a new HIV-focused spinoff company that will focus solely on advancing an HIV cure, building upon more than a decade of work by American Gene Technologies® (AGT™). Galvin provides insights on data…
Read More
The Bay Area Reporter: Endowment Honors Pioneering HIV Doctor, Dr. Conant
Original Post in The Bay Area Reporter By: Matthew S. Bajko A new endowment named in honor of the pioneering HIV physician Dr. Marcus Conant aims to help educate future generations of health care providers interested in caring for people living with HIV and…
Read More
ShareTreck: Jeff Galvin Weighs in on Addimmune’s Launch and AGT103-T Updates
American Gene Technologies® CEO Jeff Galvin joins ShareTreck host Raj Natarajan in this compelling interview to share updates on AGT103-T, as well as the launch of the new HIV-focused spinoff company – Addimmune. Following a successful Phase 1 clinical trial, Addimmune will build AGT’s success,…
Read More
NBC4: Rockville Biotech Shares Encouraging News in HIV Fight
CEO Jeff Galvin joins NBC 4 to discuss the success of AGT’s Phase 1 HIV gene and cell therapy clinical trial, as well as plans to advance to Phase 2 through Addimmune™ – a new spinoff company harnessing gene and cell therapy technologies for a…
Read More
DC News Now: Company Launches New Company “Addimmune” to Focus Exclusively on Developing Cure for HIV
Original Post in DC News Now. By: Shennekia Grimshaw American Gene Technologies (AGT™), a clinical-stage biotechnology company based in Rockville, Maryland, is launching a new company – Addimmune – to continue to develop gene and cell therapy technologies to cure HIV. Addimmune will focus…
Read More
WTOP: Rockville Gene Therapy Company Takes Next Step Toward HIV Cure
Original Post in WTOP By: Jeff Clabaugh There are treatments to keep HIV patients healthy and the virus at bay, but there is still no known cure. A Rockville, Maryland, company thinks it’s headed in the right direction. American Gene Technologies, a 15-year-old gene…
Read More
BioWorld: Addimmune Launches to Create a Functional Cure for HIV
Original Post in BioWorld. By: Lee Landenberger For Jeff Galvin, the CEO and founder of newly launched Addimmune, HIV is not a condition that’s in the rearview mirror. It needs a functional cure to save lives, make people healthier and save money that need not have…
Read MoreSubscribe to News Releases and News Updates
Subscribe to our news release and published article updates to be notified when we release new content!
Follow AGT on Social Media
AGT on Facebook
Nick Tressler, MBA | People on The Move - Washington Business Journal
bit.ly
Nick Tressler, MBA Hired at Addimmune™ / American Gene Technologies®
